Sanofi upbeat on GLP-1 diabetes drug data; Emergent wins $186M contract; Novartis smoker's cough therapy beats GSK's;

@FierceBiotech: Crucell eagerly accepts $2.3B buyout offer from J&J. Article | Follow @FierceBiotech

 @JohnCFierce: Transition's Tony Cruz gambles and fails on diabetes program, collaborating with Lilly. TT-223 bites the dust. Article | Follow @JohnCFierce

> Sanofi-Aventis says that its GLP-1 Type 2 diabetes drug, lixisenatide, significantly improved glycemic control in a late-stage trial. Sanofi has ambitious plans to expand its presence in the fast-growing diabetes drug market. Story

> Emergent BioSolutions inked a $186.6 million contract with the Department of Health and Human Services to develop a new anthrax vaccine. The five-year contract starts with a $51 million base in the first two years. News

> Novartis reports that its smoker's cough therapy, Onbrez Breezhaler, which is up for U.S. approval, proved more effective than one of GSK's treatments in a late-stage study. Report

> Eddingpharm, a specialty pharmaceutical marketing company focused on the China market, closed on a $24 million Series B financing co-led by OrbiMed Advisors Caduceus Asia Partners Fund and Domain Associates. Eddingpharm release

> Chronix Biomedical, a biomarkers company, today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix release

And Finally... Scientists say they found the ‘Homer Simpson' gene. Release